Clinical evaluation of XXXX in the treatment of @entity3283 .

@entity9989 @entity1033 @entity2194 @entity1 @entity1034 @entity146 @entity1036 @entity1066 @entity41463 @entity3283
For treatment of @entity1034 , @entity41463 ( @entity9989 ) has been the only drug available in Japan. However, IUdR is not completely satisfactory, and alternative antivirals are required. The Association for Research in Infectious @entity2194 , Japan, carried out a clinical trial in 92 cases of @entity3283 using 3 percent @entity1033 ophthalmic ointment to determine its efficacy and safety. In 63 eyes, it had an excellent effect and @entity1066 healed within seven days. In 26 eyes, it had a good effect and @entity1066 healed within 14 days or became half-size within seven days. Therefore, the response to @entity1033 in 96.8 percent of cases was excellent or good. The average healing time in 81 eyes in which @entity1066 disappeared within 14 days was 5.8 +/- 3.4 days. Including the five eyes in which @entity1066 took more than 14 days to heal, the average healing time of @entity1066 was 6.6 +/- 4.8 days. Of the 92 @entity1 treated with @entity1033 ointment, one had contact blepharoconjunctivitis and another complained of mild @entity146 . Mild @entity1036 , as another side effect of @entity1033 ointment, was observed in 22 eyes (23.9 percent) by photo-slit lamp examination, but in these @entity1 it was possible to continue treatment without complaint.
